EPS Creative Health Technology (Stock Code: 3860) Announces Interim Results for the Six Months Ended 30 September 2025

Bulletin Express
2025/11/27

EPS Creative Health Technology reported revenue of approximately HK$223.9 million for the six months ended 30 September 2025, compared with HK$346.9 million over the same period last year. The Group recorded a loss after taxation of around HK$2.6 million, versus a profit of HK$17.1 million in the corresponding period in 2024. Basic loss per share stood at 0.78 HK cent based on a weighted average of 522,177,419 shares, and the Board has not proposed an interim dividend.

According to the announcement, the Healthcare and Medicated Products Business posted a notable increase in segment revenue to HK$101.7 million, compared with HK$73.4 million a year earlier. The segment’s performance was supported by growth in its health and medicated food distribution business and by large-scale projects in its laboratory supply distribution business. The IRO with CRO Service and In-house R&D Business recorded revenue of HK$45.4 million, up from HK$28.5 million, attributed in part to the China-focused specialised CRO services. By contrast, garment segment revenue declined from HK$245.0 million to HK$76.9 million, primarily due to reduced orders from major customers in the United States and Europe.

Gross profit reached HK$37.8 million, compared with HK$49.6 million in the previous year. Segment-wise, the Healthcare and Medicated Products Business benefited from new sales channels and improved cost controls. The IRO with CRO Service saw revenue expansion but reported reduced gross profit, owing to a narrower focus in certain service areas. Within the garment segment, despite lower sales volume, cost control and higher average selling prices of womenswear and menswear helped lift the gross margin.

As of 30 September 2025, the Group had net current assets of HK$70.7 million and a gearing ratio of 0.03. Management highlighted that future strategies will focus on strengthening and expanding the core businesses—particularly in healthcare-related distribution and IRO with CRO services—while continuing to maintain a prudent approach and efficient resource use in the garment segment.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10